Previous multi-center imaging studies with 18F-FDG PET have established the presence of Parkinson's disease motor- and cognition-related metabolic patterns termed PDRP and PDCP in patients with this disorder. Given that in PD cerebral perfusion and glucose metabolism are typically coupled in the absence of medication, we determined whether subject expression of these disease networks can be quantified in early-phase images from dynamic 18F-FPCIT PET scans acquired to assess striatal dopamine transporter (DAT) binding. Methods: We studied a cohort of early-stage PD patients and age-matched healthy control subjects who underwent 18F-FPCIT at baseline; scans were repeated 4 years later in a smaller subset of patients. The early 18F-FPCIT frames, which reflect cerebral perfusion, were used to compute PDRP and PDCP expression (subject scores) in each subject, and compared to analogous measures computed based on 18F-FDG PET scan when additionally available. The late 18F-FPCIT frames were used to measure caudate and putamen DAT binding in the same individuals. Results: PDRP subject scores from early-phase 18F-FPCIT and 18F-FDG scans were elevated and striatal DAT binding reduced in PD versus healthy subjects. The PDRP scores from 18F-FPCIT correlated with clinical motor ratings, disease duration, and with corresponding measures from 18F-FDG PET. In addition to correlating with disease duration and analogous 18F-FDG PET values, PDCP scores correlated with DAT binding in the caudate/anterior putamen. PDRP and PDCP subject scores using either method rose over 4 years whereas striatal DAT binding declined over the same time period. Conclusion: Early-phase images obtained with 18F-FPCIT PET can provide an alternative to 18F-FDG PET for PD network quantification. This technique therefore allows PDRP/PDCP expression and caudate/putamen DAT binding to be evaluated with a single tracer in one scanning session.
Previous multi-center imaging studies with 18F-FDG PET have established the presence of Parkinson's disease motor- and cognition-related metabolic patterns termed PDRP and PDCP in patients with this disorder. Given that in PD cerebral perfusion and glucose metabolism are typically coupled in the absence of medication, we determined whether subject expression of these disease networks can be quantified in early-phase images from dynamic 18F-FPCIT PET scans acquired to assess striatal dopamine transporter (DAT) binding. Methods: We studied a cohort of early-stage PD patients and age-matched healthy control subjects who underwent 18F-FPCIT at baseline; scans were repeated 4 years later in a smaller subset of patients. The early 18F-FPCIT frames, which reflect cerebral perfusion, were used to compute PDRP and PDCP expression (subject scores) in each subject, and compared to analogous measures computed based on 18F-FDG PET scan when additionally available. The late 18F-FPCIT frames were used to measure caudate and putamen DAT binding in the same individuals. Results: PDRP subject scores from early-phase 18F-FPCIT and 18F-FDG scans were elevated and striatal DAT binding reduced in PD versus healthy subjects. The PDRP scores from 18F-FPCIT correlated with clinical motor ratings, disease duration, and with corresponding measures from 18F-FDG PET. In addition to correlating with disease duration and analogous 18F-FDG PET values, PDCP scores correlated with DAT binding in the caudate/anterior putamen. PDRP and PDCP subject scores using either method rose over 4 years whereas striatal DAT binding declined over the same time period. Conclusion: Early-phase images obtained with 18F-FPCIT PET can provide an alternative to 18F-FDG PET for PD network quantification. This technique therefore allows PDRP/PDCP expression and caudate/putamen DAT binding to be evaluated with a single tracer in one scanning session.
Authors: Martin Niethammer; Chris C Tang; An Vo; Nha Nguyen; Phoebe Spetsieris; Vijay Dhawan; Yilong Ma; Michael Small; Andrew Feigin; Matthew J During; Michael G Kaplitt; David Eidelberg Journal: Sci Transl Med Date: 2018-11-28 Impact factor: 17.956
Authors: Chris C Tang; Florian Holtbernd; Yilong Ma; Phoebe Spetsieris; Alice Oh; Gereon R Fink; Lars Timmermann; Carsten Eggers; David Eidelberg Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Chris C Tang; Kathleen L Poston; Thomas Eckert; Andrew Feigin; Steven Frucht; Mark Gudesblatt; Vijay Dhawan; Martin Lesser; Jean-Paul Vonsattel; Stanley Fahn; David Eidelberg Journal: Lancet Neurol Date: 2010-01-08 Impact factor: 44.182
Authors: Martin Niethammer; Chris C Tang; Andrew Feigin; Patricia J Allen; Lisette Heinen; Sabine Hellwig; Florian Amtage; Era Hanspal; Jean Paul Vonsattel; Kathleen L Poston; Philipp T Meyer; Klaus L Leenders; David Eidelberg Journal: Brain Date: 2014-09-09 Impact factor: 13.501
Authors: Renata P Lerner; Veronica Francardo; Koji Fujita; Zisis Bimpisidis; Vincent A Jourdain; Chris C Tang; Stephen L Dewey; Thomas Chaly; M Angela Cenci; David Eidelberg Journal: Sci Rep Date: 2017-11-22 Impact factor: 4.379
Authors: Leonie Beyer; Alexander Nitschmann; Henryk Barthel; Thilo van Eimeren; Marcus Unterrainer; Julia Sauerbeck; Ken Marek; Mengmeng Song; Carla Palleis; Gesine Respondek; Jochen Hammes; Michael T Barbe; Özgür Onur; Frank Jessen; Dorothee Saur; Matthias L Schroeter; Jost-Julian Rumpf; Michael Rullmann; Andreas Schildan; Marianne Patt; Bernd Neumaier; Olivier Barret; Jennifer Madonia; David S Russell; Andrew W Stephens; Sigrun Roeber; Jochen Herms; Kai Bötzel; Johannes Levin; Joseph Classen; Günter U Höglinger; Peter Bartenstein; Victor Villemagne; Alexander Drzezga; John Seibyl; Osama Sabri; Matthias Brendel Journal: Eur J Nucl Med Mol Imaging Date: 2020-04-21 Impact factor: 9.236